

The European LeukemiaNet

ELN Home

- Calendar
- ELN-Symposia
- Current Meetings
- The Project
- ELN Structure
- ELN Foundation
- ESF
- Wilsede synapses
- Contact Info
- Information Letter
- E-Newsletter
- Countries
- Translation Leukemia
- Disclaimer

The European LeukemiaNet is an EU-funded organisation of physicians, scientists and patients with interest in leukemia. It aims to improve the treatment and knowledge about Leukemia in Europe and spread excellence. The website delivers information for physicians, patients (e.g. patient organisations in Europe), ongoing clinical trials and further information about the disease. You can get information about the European LeukemiaNet in various european languages. The European LeukemiaNet is funded by the 6th Framework Program of the European Community.



News	Events
<p><input type="checkbox"/> CML patient information The Czech Leukemia Study Group for Life (CELL) published a Czech information for CML-patients and their relatives.</p> <p><input type="checkbox"/> European Medicines Agency releases a public database of suspected adverse drug reaction reports In May 2012 the European Medicines Agency launched the new website www.adrreports.eu publishing suspected side-effect reports of drugs authorised in the European Economic Area. The website for the general public is available in all official European languages.</p> <p><input type="checkbox"/> ARD12042 New trial: A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea</p> <p><input type="checkbox"/> BUM-5/GVH New trial: Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GVHD</p> <p><input type="checkbox"/> CAMN107 Y 2101 New trial: A Single-arm Dose-finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE225 in Combination With Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Have Failed Prior Therapy With Other BCR-ABL Tyrosine-kinase Inhibitors</p>	<p>Fr 2012/11/09 - Su 2012/11/11 ELN Frontiers Meeting 2012</p> <p>Sa 2012/12/08 - Tu 2012/12/11 54. ASH Annual Meeting and Exposition</p> <p>Tu 2013/02/05 - We 2013/02/06 10th Annual Symposium of the European LeukemiaNet</p>

The European LeukemiaNet

189 Participating Centers in 38 Countries (1000 Researchers and Associates) are cooperating in the European Leukemia Net. The objective is to integrate the 108 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their 105 interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia related research and health care (data updated March 2012).

Key words: leukemia, leukæmia, leukämie, leucemie, leucémie, leucemia, leukemi, leukemie, lösemi, لوكيميا, سرطان الدم, 白血病, leukemija, leukemije, leukemio, biaskaka, עֲרֵבוֹת הַדָּם, לוקמיה

Search:

Dates & Meetings

October 2012 « | »

mo	tu	we	th	fr	sa	su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

November 2012 « | »

mo	tu	we	th	fr	sa	su
		1	2	3	4	
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

RSS

Online Registration

How to join the European LeukemiaNet

European Leukemia Trial Registry (ELTR)

European Treatment and Outcome Study

ELTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe

European Science Foundation

The ELN is funded through a Research Networking Programme (RNP), initiated by the European Science Foundation

ELN Foundation

European ■ LeukemiaNet
The ELN Foundation is a non-profit charitable organisation, which supports the goals of the European LeukemiaNet

Video Clips

European ■ LeukemiaNet